Propeller: The Digital Therapeutic Cutting Asthma Hospitalisations Before They Happen
What is Propeller? Propeller is a connected inhaler and digital therapeutic platform that pairs attachable Bluetooth sensors with a patient mobile app and clinician dashboard to monitor inhaler use, track symptoms, and deliver personalized insights. The system captures date/time and context of rescue and controller inhaler actuations, analyzes usage patterns, detects early signs of loss […]
Feature Categories
What is Propeller?
Propeller is a connected inhaler and digital therapeutic platform that pairs attachable Bluetooth sensors with a patient mobile app and clinician dashboard to monitor inhaler use, track symptoms, and deliver personalized insights. The system captures date/time and context of rescue and controller inhaler actuations, analyzes usage patterns, detects early signs of loss of control, and surfaces actionable alerts and adherence coaching to patients and care teams.
Deployed across asthma and COPD populations, Propeller supports population health programs, clinician workflows, and payer pilots by turning medication events into real-time, evidence-ready signals that enable prevention, targeted outreach, and outcome measurement.
Why Leading Healthcare Teams Trust Propeller
- Multiple FDA 510(k) clearances received since 2012, with at least eight separate FDA clearances for use with various inhalers including GSK's Ellipta, Boehringer Ingelheim's Respimat, and AstraZeneca's Symbicort
- FDA-granted marketing claims for improved adherence and reduction in exacerbations
- CE marking approval for international markets
- Randomised clinical trial with 495 patients demonstrated significantly decreased rescue inhaler use, increased symptom-free days, and improved asthma control scores
- Studies showed 53% reduction in emergency department visits and 57% reduction in combined ED visits and hospitalisations
- Large public health study demonstrated 78% reduction in rescue inhaler use and 48% improvement in symptom-free days
- Named one of Fast Company's 50 Most Innovative Companies in 2017
- Recipient of American Telemedicine Association's 2016 President's Award for Innovation in Remote Healthcare
- Winner of Digital Health Hub Foundation Award in health equity category in 2023
- Recognised as White House Champion of Change and received TEDMED Innovation Showcase award
- Acquired by ResMed in December 2018 for $225 million, providing substantial corporate backing and resources
- Operates as standalone business within ResMed's Respiratory Care portfolio maintaining its partnerships and solutions
- Founding member of the Digital Therapeutics Alliance, established in 2017
- General Manager Susa Monacelli elected to Digital Therapeutics Alliance Board of Directors in 2024
- Established 65 commercial programs with pharmaceutical companies, pharmacy benefit managers, and major healthcare systems
- Collaborations with pharmaceutical companies including GSK, Boehringer Ingelheim, AstraZeneca, and Novartis
Top 3 Pain Points Propeller Fixes in Healthcare
| Problem in Respiratory Care | How Propeller Solves It |
|---|---|
| 1. Poor inhaler adherence and incorrect usage lead to uncontrolled asthma/COPD. | Smart inhaler sensors track medication use and provide reminders and personalised coaching to improve adherence. |
| 2. Exacerbations are identified too late, causing avoidable ER visits and hospitalisations. | Real-time monitoring detects early signs of declining control and alerts care teams for timely intervention. |
| 3. Clinicians lack visibility into patient behaviour between visits. | Provides continuous data and dashboards so providers can make proactive, evidence-based decisions. |
Feature Category Summary: Propeller
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | Propeller Health’s platform and sensors are repeatedly described as FDA‑cleared and CE‑marked digital therapeutics for asthma and COPD, with multiple 510(k) clearances covering the Propeller platform in association with inhalers such as GSK’s Ellipta, Diskus, Boehringer’s Respimat, and AstraZeneca’s Symbicort, indicating formal SaMD review and device‑level quality and software controls. These clearances, together with Health Canada registration, show that Propeller operates under regulated medical‑device frameworks with auditable safety and performance documentation. | YES |
| Clinical Trial Support | Propeller is characterized as a remote monitoring and self‑management platform that tracks inhaler use, symptoms, and environmental exposures and feeds data to clinicians through portals and EHR integrations to guide ongoing care, but product descriptions focus on disease management, not on designing or running clinical trials. No public documentation was found indicating that Propeller includes dedicated modules for trial protocol design, recruitment, investigational product management, or trial reporting. | NO |
| Supply Chain & Quality | Propeller’s offering comprises connected inhaler sensors, mobile apps, analytics, and clinician dashboards to optimize adherence and symptom control, with no mention of managing pharmaceutical manufacturing processes, serialization, logistics, or counterfeit‑drug detection. No public documentation was found describing capabilities for manufacturing integrity or end‑to‑end supply‑chain quality assurance. | NO |
| Efficiency & Cost-Saving | Across more than 150 peer‑reviewed studies, Propeller’s platform has demonstrated not only improved control and quality of life but also reductions in emergency department visits, hospitalizations, and healthcare utilization, thereby lowering healthcare costs. Budget impact analyses and collaborations with health systems report decreased exacerbations and hospital use among COPD and asthma patients using the platform, supporting clear cost‑saving and efficiency benefits for payers and providers. | YES |
| Scalable / Enterprise-Grade | Propeller is deployed as a remote monitoring program across large health systems (e.g., UC Davis Health and Dignity Health) with EHR‑integrated workflows for hundreds of physicians and thousands of high‑risk patients, and is also used globally with multiple pharma partners (GSK, Boehringer Ingelheim, AstraZeneca, Orion), indicating enterprise‑scale implementations. These deployments, combined with FDA/CE regulatory status and payer collaborations, show a mature, enterprise‑grade SaaS/hybrid platform rather than a small pilot‑level tool. | YES |
| HIPAA Compliant | Propeller’s positioning as a remote monitoring platform embedded into U.S. health‑system EHRs to handle identifiable inhaler use and respiratory data for patients with asthma and COPD implies operation under HIPAA, and health‑system case descriptions highlight secure transmission of PHI into EHR workflows; however, the sourced public summaries and alliance profiles reviewed here do not explicitly quote the phrase “HIPAA‑compliant” or detail specific HIPAA certifications. No explicit HIPAA‑compliance statement was found in the referenced documents, so strict evidence under this rubric is not met. | NA |
| Clinically Validated | Propeller’s digital therapeutics platform is reported to have been evaluated in more than 150 peer‑reviewed studies and articles in asthma and COPD, consistently demonstrating improved disease control, increased adherence, better quality of life, and reductions in emergency visits and hospitalizations. These published clinical and health‑economic evaluations, in combination with multiple FDA 510(k) clearances for its sensors and platform, constitute extensive clinical validation for its intended use as a respiratory digital therapeutic and remote monitoring solution. | YES |
| EHR Integration | UC Davis Health and Dignity Health explicitly report integrating Propeller’s remote monitoring platform into their EHR systems, allowing Propeller data to be ordered and managed like any other treatment, with inhaler‑use data transmitted directly into the EHR and embedded visualizations and notifications available in clinician workflows. These integrations streamline enrollment and monitoring (e.g., reducing enrollment time by 75–80%) and enable clinicians to identify and intervene on at‑risk patients from within the EHR, confirming real‑world EHR integration as a core feature. | YES |
| Explainable AI | Propeller’s platform uses sensors, mobile apps, and analytics, including an FDA‑cleared sensor upgrade that predicts COPD/asthma exacerbations, but public descriptions focus on the prediction and alerts, not on user‑facing explanation of how those predictions are derived. No public documentation was found describing explicit explainable‑AI tooling such as feature‑importance visualizations, model‑explanation interfaces, or regulatory‑style transparency modules. | NA |
| Real-Time Analytics | Propeller captures inhaler events via connected sensors and transmits data to patient apps and clinician dashboards, enabling near‑real‑time remote monitoring of medication use, rescue inhaler overuse, and symptom patterns. Health‑system deployments describe real‑time data, alerts, and notifications embedded into EHR workflows so clinicians can quickly identify patients who need intervention, aligning with real‑time analytics for respiratory management. | YES |
| Bias Detection | Although Propeller has a large evidence base, the reviewed descriptions and studies emphasize clinical and economic outcomes (adherence, exacerbations, utilization) and do not report built‑in platform features for measuring or mitigating algorithmic bias across demographic or clinical sub‑cohorts. No public documentation was found that describes fairness metrics, bias‑auditing tools, or systematic bias detection as part of the product. | NO |
| Ethical Safeguards | Propeller’s implementation as an FDA‑cleared medical device used under clinician supervision—and integrated into health‑system programs that enroll eligible patients and use data for proactive interventions—ensures that human clinicians remain in the loop for treatment decisions and escalations. However, publicly available summaries do not detail explicit in‑product ethical governance modules such as configurable consent workflows, AI use‑case restrictions, or bias‑reporting dashboards beyond standard clinical oversight, regulatory clearance, and privacy practices. | NA |
Risks & Limitations: Propeller
-
Predictive and analytic performance depends on consistent sensor use and high-quality actuation data; missing or mispaired sensors reduce signal fidelity.
-
Outputs are decision-support; clinician validation and appropriate follow-up are required before changing therapy.
-
Patient adoption and adherence to sensor/app workflows vary; low engagement reduces clinical impact.
-
Integration with EHRs and payer systems can require IT effort, governance, and contractual arrangements; reimbursement and coverage policies are variable across markets.
Tags
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
Stephen
Founder of HealthyData.Science · 20+ years in life sciences compliance & software validation · MSc in Data Science & Artificial Intelligence.